Product Pipeline

This list contains information about the development status of unapproved drugs or unapproved indications. Nothing herein are intended to constitute promotion or advertisement of pharmaceutical products (including products currently in development).

IND Code

 Dosage Form Features Indications Development Locations Development Stage
TAS-115 Oral Multi-kinase inhibitor Osteosarcoma Japan Phase III
Prostate cancer Japan Phase II
Chronic fibrosing interstitial lung diseases with a progressive phenotype Japan Phase II
TAS-116 Oral HSP90 inhibitor
Solid tumors US Phase I
Europe Phase I
Prostate cancer Japan Phase II
TAS-117 Oral AKT inhibitor Solid tumors with germline PTEN mutations Japan Phase II
US Phase II
Europe Phase II
TAS-120
 Oral FGFR inhibitor　 Breast cancer US Phase II
Europe Phase II
FGFR aberrations cancer Japan Phase II
US Phase II
Europe Phase II
Urothelial cancer US Phase II
Europe Phase II
Solid tumors(esophageal cancer, pancreatic cancer） US Phase II
Europe Phase II
TAS0728 Oral 　 Solid tumors US Phase I/II
Europe Phase I/II
TAS0612 Oral Solid tumors US

Phase I
Europe Phase I
TAS0953 Oral Solid tumors Japan Phase I/II
TAS3351 Oral Non-small cell lung Japan Phase I/II
US Phase I/II
Europe Phase I/II
TAS1440 Oral Acute myeloid leukemia US Phase I
TAS1553 Oral Acute myeloid leukemia US Phase I
TAS2940 Oral Solid tumors US Phase I
Europe Phase I
TAS6417 Oral EGFR inhibitor Non-small cell lung cancer Japan Phase III
US Phase III
Europe Phase III
ET-743 Injection Ovarian cancer Japan Phase I
AB122 Injection Anti-PD-1 antibody Solid tumors Japan Phase I
AB122+TAS-115 Injection + oral Anti-PD-1 antibody + Multi-kinase inhibitor Solid tumors Japan Phase I
AB122+TAS-116 Injection + oral Anti-PD-1 antibody + HSP90 inhibitor Solid tumors Japan Phase I
AB122+TAS-120 Injection + oral Anti-PD-1 antibody + FGFR inhibitor Soild tumors Japan Phase I
AB122+AB154 Injection Anti-PD-1 antibody + anti-TIGIT antibody Upper gastrointestinal tract cancer Japan Phase III
Non-small cell lung cancer Japan Phase III
ASTX727 Oral DNA methyltransferase inhibitor Myelodysplastic syndromes Japan Phase I
China Phase I/II
Acute myeloid leukemia US Phase II
ASTX660 Oral IAP inhibitor T-cell lymphoma Japan Phase I
ASTX660+ASTX727 Oral T-cell lymphoma US Phase I
ASTX029 Oral ERK1/2 inhibitor Solid tumors US Phase I/II
ASTX295 Oral MDM2 inhibitor Solid tumors US Phase I/II
ASTX030 Oral Myelodysplastic syndromes Japan Phase I
Myelodysplastic syndromes, Chronic Myelomonocytic Leukemia, Acute myeloid leulemia US Phase II/III
TAS-205 Oral PGD synthase inhibitor Duchenne muscular dystrophy(DMD) Japan Phase III
TAS5315 Oral BTK inhibitor Rheumatoid arthritis(RA) Japan Phase II
Chronic spontaneous urticaria Japan Phase II
TAC-302 Oral 　 Detrusor underactivity with overactive bladder Japan Phase II
TAS-303 Oral Selective noradrenaline reuptake inhibitor Stress urinary incontinence Japan Phase II

As of Dec. 31, 2024